INVENTORS: Prof. Joseph A. Aladesanmi, Mr. Ayodeji O. Oriola, Prof. Gilbert Arthur, Dr. Frank Schweizer
The invention is in the field of natural products drug discovery, public health and pharmacy. The invention is a discovery of a new anti-cancer oleanolic acid glycoside from the leaf of Massulariaacuminatausing methanethiosulfonate (MTS) cell proliferation assay with Chlorambucil (200 µg/mL) as standard drug. The leaf ethanolic extract demonstrated the highest anti-cancer activity amongst other plant parts and was fractionated into n-hexane, ethylacetate, n-butanol and aqueous fractions. The most active ethylacetate fraction was purified on repeated column chromatography plus preparative thin-layer chromatography (PTLC) which afforded the new compound and was characterized as α-L-rhamnopyranosyl-(1→2)-3-O-α-D-glucopyranosyloleanolic acid.
The compound demonstrated higher anti-cancer activity than the standard drug used. It was cytotoxic against breast (MDA-MB-231, Hs578t and JIMT-1), cervical (HeLa), prostate (PC3 and DU145), and pancreatic (MiaPaCa2) cancer cell lines at 25 µg/mL compared to the standard drug at 200 µg/mL. The mechanism of action of this compound was found to be by apoptosis, which is a lead broad spectrum anticancer compound against prostate, breast, cervical, and pancreatic cancers, hence the patent.
The patent was processed through the OAU’s IPTTO Office located at the former Distance Learning Complex, off road 1, OAU, Ile-Ife. The Office is always ready to assist researchers/inventors process their Intellectual Property Rights (IPRs) resulting from research activities. IPRs are Intellectual Assets that enhance the value of invention for the purpose of commercialization through outright sale, exploitation or licensing of the invention. IP Assets are more relevant for meeting market needs and wealth creation through university-industry linkage, technology transfer and licensing in this knowledge-driven age.